Details for Patent: 10,751,342
✉ Email this page to a colleague
Which drugs does patent 10,751,342 protect, and when does it expire?
Patent 10,751,342 protects IMBRUVICA and is included in three NDAs.
Protection for IMBRUVICA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has fifty-nine patent family members in eighteen countries.
Summary for Patent: 10,751,342
| Title: | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
| Abstract: | Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile. |
| Inventor(s): | Buggy; Joseph J. (Mountain View, CA), Fyfe; Gwen (San Francisco, CA), Honigberg; Lee (San Francisco, CA), Loury; David J. (Incline Village, NV) |
| Assignee: | Pharmacyclics LLC (Sunnyvale, CA) |
| Application Number: | 16/748,142 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 10,751,342
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacyclics Llc | IMBRUVICA | ibrutinib | SUSPENSION;ORAL | 217003-001 | Aug 24, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA | ⤷ Sign Up | ||||
| Pharmacyclics Llc | IMBRUVICA | ibrutinib | SUSPENSION;ORAL | 217003-001 | Aug 24, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF ADULT PATIENTS WITH SMALL LYMPHOCYTIC LYMPHOMA (SLL) WITH 17P DELETION | ⤷ Sign Up | ||||
| Pharmacyclics Llc | IMBRUVICA | ibrutinib | SUSPENSION;ORAL | 217003-001 | Aug 24, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF ADULT PATIENTS WITH SMALL LYMPHOCYTIC LYMPHOMA (SLL) | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,751,342
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2011261185 | ⤷ Sign Up | |||
| Australia | 2015275321 | ⤷ Sign Up | |||
| Australia | 2018204179 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
